Ainos, Inc. - AIMD STOCK NEWS

Ainos, Inc. (NASDAQ: AIMD) has received positive FDA feedback on its Biologics License Application (BLA) for treating Sjögren's syndrome following two successful Phase 3 studies. The company is seeking out-licensing partnerships for five new drug candidates based on its low-dose oral interferon-alpha formulation, VELDONA®. These candidates have shown promising results in Phase 2 trials across various conditions, including aphthous stomatitis and influenza. Ainos aims to accelerate the commercialization of VELDONA® through these collaborations, having invested nearly $40 million in its development.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced it is pursuing out-licensing opportunities for five new drug candidates of its low-dose oral interferon-alpha formulation, VELDONA. The candidates have successfully completed Phase 2 trials, with plans to accelerate them to Phase 3 and commercialization. The trials demonstrated VELDONA's effectiveness in treating various conditions, including Sjögren's syndrome and influenza. Ainos has invested nearly $40 million in the development of VELDONA and aims to enhance autoimmunity while minimizing side effects compared to high-dose injections.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced positive results from its preclinical efficacy study of VELDONA®, a low-dose oral interferon formulation, against the Omicron variant of SARS-CoV-2. The study demonstrated significant stabilization in lung inflammation and recovery in hamsters treated with VELDONA®. The results led to an application for Phase 2 clinical trials in patients with mild COVID-19. The treatment showed a better recovery trend, with no observed mixed-cellular inflammation in the VELDONA® group, compared to 50% in the placebo group.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, aimed at treating mild COVID-19 symptoms. The trial will assess VELDONA's efficacy compared to standard care in a multicenter study in Taiwan. If successful, this could enhance treatments for COVID-19 and other viral infections.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture, and package its VELDONA product candidates. This agreement aligns with Ainos' plans to submit an IND application for a Phase 2 study to the FDA by year-end. Additionally, Ainos is pursuing clinical trials for VELDONA against COVID-19 and has plans for further studies on thrombocytopenia and Sjögren's syndrome in 2023. This partnership aims to enhance Ainos' manufacturing capabilities and streamline its clinical trial preparations.

Ainos, a diversified medtech company, reported its second quarter financial results for 2022, showing a substantial revenue increase of 213.6% to US$636,627, driven by sales of COVID-19 Antigen Rapid Test Kits. Gross profit reached US$317,664, with a gross margin of 49.9%. However, total operating expenses surged 163.0% to US$2,261,960, impacting net loss, which increased to US$1,954,032. The company highlighted successful product developments, including an Emergency Use Authorization for its COVID-19 test kit in Taiwan, and progress on its VELDONA antiviral formulation.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced the closing of its public offering of 780,000 units at $4.25 per unit, yielding approximately $3.3 million in gross proceeds. Each unit includes one share of common stock and a warrant for one share. The stock underwent a reverse split at a 1-for-15 ratio, effective August 8, 2022. Additionally, the company granted underwriters a 45-day option to purchase an extra 117,000 shares and/or warrants. The offering was conducted under its SEC registration statement, effective as of August 8, 2022.

Ainos, Inc. (OTC PINK: AIMD) announced positive results from a preclinical study of its oral interferon formulation, VELDONA, against COVID-19 in hamsters. The study showed that VELDONA significantly reduced weight loss and viral loads in infected hamsters compared to a control group. Notably, the VELDONA group exhibited a maximum viral load reduction of 720510.66 on day six. Ainos plans to prepare application documents for FDA Phase 2/3 clinical trials, aiming to establish VELDONA's efficacy against COVID-19 and other viral infections.

Ainos, Inc. (OTC PINK:AIMD) has launched the Ainos SARS-CoV-2 Antigen Rapid Self-Test Kit in Taiwan, following Emergency Use Authorization from the Taiwan Food and Drug Administration on June 13, 2022. This at-home test kit enables users to detect the presence of SARS-CoV-2, including the Omicron variant, yielding results in just 15 minutes. The company has previously marketed a professional-use version since June 2021. Ainos aims to meet the rising demand for COVID-19 testing amidst increasing cases, thereby supporting public health measures.